Skip to content

Acute Changes in Bioimpedance During Cardiac Resynchronization Therapy

Acute Changes in Bioimpedance During Cardia Resynchronization Therapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03640000
Acronym
Impel
Enrollment
60
Registered
2018-08-21
Start date
2015-01-31
Completion date
2021-12-31
Last updated
2018-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Systolic

Brief summary

This study aims at Optimizing measured parameters to reflect underlying pathology in dyssynchronous hearts. This is an experimental study in patients were bioimpedance measurements are performed during implantation.

Detailed description

Patients who are eligible for implantation af a Cardiac Resynchronization Therapy Device according to European Society of Cardiology guidelines are included. Measurements are performed on implanted leads and stored for post Processing. The study entry ends for each patient With completion of the implantation procedure.

Interventions

DIAGNOSTIC_TESTImpedance measurements in Cardiac Resynchronization therapy

Bioimpedance measurements

Sponsors

Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

\- Indication for Cardiac resynchronization therapy or Upgrade of exciting Device according to the current European Society of Cardiology guidelines.

Design outcomes

Primary

MeasureTime frameDescription
Optimization of Bioimpedance measurements3 yearsAcquisition of absolute and imaginary bioimpedance signals from electrodes of known location within the heart at different input current frequencies. Pacing is performed from Three different electrodes during acquisition of bioimpedance acquisition forming Three different groups. Wavelets of the signals are analyzed within each Group and compared within the Group and between the Groups. Optimization is achived when a discrimination factor that is calculated is improved.

Countries

Norway

Contacts

Primary ContactHans Henrik Odland, MD, PhD
h.h.odland@medisin.uio.no23070000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026